SCHEMBL2601974

SCHEMBL2601974

CC(=O)NCc1ccc(OC(C)=O)c(OC(C)=O)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
INSR P06213 1/20 0.54
IGF1R P08069 1/20 0.54
ALDH1A1 P00352 5/20 0.53
TRPV1 Q8NER1 1/20 0.51
PTGS1 P23219 1/20 0.50
KMT2A Q03164 2/20 0.49
KDM4E B2RXH2 2/20 0.49
RAB9A P51151 2/20 0.49
GAA P10253 1/20 0.49
TSHR P16473 1/20 0.49
CFD P00746 1/20 0.47
CYP4F2 P78329 1/20 0.47
CYP4A11 Q02928 1/20 0.47
MEN1 O00255 1/20 0.47
MAPT P10636 2/20 0.47
HDAC1 Q13547 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
CCR5 P51681 2/20 0.45
POLB P06746 2/20 0.45
TOP1 P11387 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2009538 0.92 ALDH1A1 (0.65) ALDH1A1PTGS1KMT2ATSHRMEN1
SCHEMBL179008 0.90 INSR (0.54) INSRIGF1RALDH1A1TRPV1PTGS1
SCHEMBL3818808 0.88 ALDH1A1 (0.60) ALDH1A1PTGS1KMT2ATSHRMEN1
SCHEMBL3818805 0.88 ALDH1A1 (0.60) ALDH1A1PTGS1KMT2ATSHRMEN1
SCHEMBL179003 0.87 TRPV1 (0.59) INSRIGF1RALDH1A1TRPV1PTGS1
SCHEMBL23417795 0.86 CYP4F2 (0.51) ALDH1A1KMT2ACFDCYP4F2CYP4A11
SCHEMBL8348098 0.86 ALDH1A1 (0.62) INSRIGF1RALDH1A1TRPV1PTGS1
SCHEMBL8422221 0.86 ALDH1A1 (0.62) INSRIGF1RALDH1A1TRPV1PTGS1
SCHEMBL179000 0.86 POLB (0.52) INSRIGF1RALDH1A1TRPV1KMT2A
SCHEMBL179006 0.84 TOP1 (0.57) INSRIGF1RALDH1A1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163957-B2 Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes and parkinson's disease PROTEOTECH, INC. (US) 2012-04-24 US disclosed
US-20110172239-A1 Compounds, Compositions and Methods for the Treatment of Amyloid Diseases and Synucleinopathies such as Alzheimer's Disease, Type 2 Diabetes and Parkinson's Disease PROTAMED, INC. 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172239-A1 Compounds, Compositions and Methods for the Treatment of Amyloid Diseases and Synucleinopathies such as Alzheimer's Disease, Type 2 Diabetes and Parkinson's Disease IAPP, SNCA, APP INSR 295/4885IGF1R 3353/4885ALDH1A1 2631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.